News

April 16, 2024.  DeepRx team is awarded an NSF grant supporting the market analyses and business development. 

• Feb 6, 2024.  Our article on developing and validating DeepRx COLOXIS signature for predicting oxaliplatin benefit is published by the Journal of Clinical Oncology: https://ascopubs.org/doi/10.1200/JCO.23.01080.  The NRG Oncology, a national clinical trial organization for managing large clinical trials, also published a press release highlighting this impactful work. As the first predictive AI model for oxaliplatin benefit, the COLOXIS signature will significantly improve the accuracy of colon cancer (CC) adjuvant therapies, as shown in the diagram.  It will double the response rate to oxaliplatin in the COLOXIS-positive group patients and, on the other hand, save half of patients from unnecessary oxaliplatin-induced neural toxicity.  This will impact close to a million patients worldwide. 

• May, 2022.  The abstract of our study of using DeepRx COLOXIS system to guide regimen selection for adjuvant therapy of colon cancer is published in ASCO 2022. The significance of this work is two-fold: First, if applied in practice, the system potentially can improve clinical outcomes of over a million colorectal cancer patients worldwide. Second, this study provides the first evidence that AI methods can be used to predict efficacy of chemotherapy and biological drugs in a real clinical setting.  Since chemo drugs remain the backbone of contemporary oncology, this study opens the new direction of developing more AI models to guide application of more chemotherapy agents to treat different cancers, which will benefit millions of patients.